Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 723 JPY 7.59% Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Perseus Proteomics Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Gross Profit
ÂĄ87.7m
CAGR 3-Years
11%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Gross Profit
ÂĄ19.2B
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
72%
PeptiDream Inc
TSE:4587
Gross Profit
ÂĄ35.5B
CAGR 3-Years
39%
CAGR 5-Years
46%
CAGR 10-Years
56%
Takara Bio Inc
TSE:4974
Gross Profit
ÂĄ24.8B
CAGR 3-Years
-15%
CAGR 5-Years
3%
CAGR 10-Years
7%
Pharma Foods International Co Ltd
TSE:2929
Gross Profit
ÂĄ48.8B
CAGR 3-Years
7%
CAGR 5-Years
42%
CAGR 10-Years
49%
C
Cuorips Inc
TSE:4894
Gross Profit
ÂĄ9.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
10.3B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
719.16 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Gross Profit?
Gross Profit
87.7m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Gross Profit amounts to 87.7m JPY.

What is Perseus Proteomics Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
-19%

Over the last year, the Gross Profit growth was 1%. The average annual Gross Profit growth rates for Perseus Proteomics Inc have been 11% over the past three years , -19% over the past five years .

Back to Top